Zynex develops, manufactures, markets and sells medical devices used for nerve stimulation, pain management, and rehabilitation, as well as non-invasive fluid, sepsis, and laser-based pulse oximetry ...

Zynex specializes in non-invasive pain management and patient monitoring, with promising advancements. Read why I think ZYXI ...

Zynex (NASDAQ:ZYXI – Get Free Report) had its price objective lowered by equities researchers at HC Wainwright from $17.00 to $15.00 in a research note issued on Wednesday,Benzinga reports. The ...

Zynex, Inc. ( NASDAQ:ZYXI ) just released its latest full-year report and things are not looking great. It wasn't ...

Fintel reports that on March 12, 2025, Ladenburg Thalmann downgraded their outlook for Zynex (NasdaqGS:ZYXI) from Buy to ...

Q4 2024 Earnings Call Transcript March 11, 2025 Operator: Good afternoon, ladies and gentlemen, and welcome to the Zynex ...

Law Offices of Howard G. Smith announces an investigation on behalf of Zynex, Inc. ("Zynex" or the "Company") (NASDAQ: ZYXI) investors concerning the Company's possible violations of federal ...

The Law Offices of Frank R. Cruz announces an investigation of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) on behalf of investors concerning ...

Despite a net loss and TRICARE payment suspension, Zynex Inc (ZYXI) shows resilience with revenue growth and strategic ...

Zynex (ZYXI) stock drops as RBC Capital Market downgrades following the company's Q4 2024 earnings report. Read more here.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ICU Medical (ICUI – Research Report) and ...

ZYNEX ($ZYXI) posted quarterly earnings results on Tuesday, March 11th. The company reported earnings of -$0.02 per share, missing estimates of $0.09 by $0.11. The ...